SCHEMBL3307634

SCHEMBL3307634

C=CC[S+]([O-])CC=C[S]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9635 0.81
Ammonia Solution, Strong SCHEMBL10454832 0.78
SCHEMBL16201955 0.75
SCHEMBL4329032 0.75
SCHEMBL20817064 0.75
SCHEMBL4329029 0.75
Allylamine SCHEMBL29212624 0.70 ALDH1A1 (0.53)
SCHEMBL11873208 0.70
SCHEMBL9945299 0.70
SCHEMBL31202551 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149940-A1 Integrin Modulators and Methods for Their Use BILLINGS PHARMACEUTICALS, INC. 2012-06-14 US disclosed
US-20120149940-A1 Integrin Modulators and Methods for Their Use BILLINGS PHARMACEUTICALS, INC. 2012-06-14 US disclosed
US-20100099917-A1 Integrin modulators and methods for their use BILLINGS PHARMACEUTICALS, INC. 2010-04-22 US disclosed
US-20080234388-A1 Integrin Modulators and Methods for their Use BILLINGS PHARMACEUTICALS, INC. 2008-09-25 US disclosed
US-20080234388-A1 Integrin Modulators and Methods for their Use BILLINGS PHARMACEUTICALS, INC. 2008-09-25 US disclosed
EP-1737816-A1 INTEGRIN MODULATORS AND METHODS FOR THEIR USE Billings Pharmaceuticals, Inc. (US) 2007-01-03 EP disclosed
WO-2005087717-A1 INTEGRIN MODULATORS AND METHODS FOR THEIR USE BILLINGS PHARMACEUTICALS INC. (US) 2005-09-22 WO disclosed